Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Opposition to the buyout deal Bristol-Myers Squibb Co (NYSE:BMY) negotiated with Celgene Corporation (NASDAQ:CELG) in January is rising and could potentially impede the M&A momentum seen in the biotech space this year.
What Happened
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Wellington Management Co, which owns an 8.3-percent stake in Bristol-Myers Squibb, said Thursday that it does not believe the Celgene deal is an attractive path toward accomplishing the goal of securing differentiated science and broadening Bristol-Myers Squibb's future revenue base.
Reacting to Wellington Management's stance, Bristol-Myers Squibb's CEO Giovanni Caforio reportedly said in an internal memo to employees that he is disappointed with the development and is continuing talks with shareholders to impress upon them the unique opportunity the deal presents for the creation of sustainable value.
Close on the heels of Wellington Management making its opposition public, activist investor Starboard Value — which also owns shares in Bristol-Myers Squibb — joined the chorus.
In a letter to shareholders, Starboard said it believes the Celgene acquisition is not in the best interest of Bristol-Myers shareholders.
The firm asked shareholders to vote down the "ill-advised" transaction and to vote for the slate of director candidates nominated by the activist investor at the 2019 annual meeting.
"Wellington's 8-percent ownership of BMY adds weight to Starboard's nomination of five BMY board seats and could mount a proxy fight," Bank of America Merrill Lynch analyst Ying Huang said in a Thursday note.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
The analyst also brought up the possibility of Wellington and Starboard seeking a white knight to bid for Bristol-Myers Squibb — or working with the company's shareholders to block the Celgene deal.
Incidentally, Amgen, Inc. (NASDAQ:AMGN) and Sanofi SA (NASDAQ:SNY) are reportedly interested in buying out Celgene.
What's Next
The action now shifts to the Bristol-Myers Squibb's 2019 annual shareholder meeting scheduled for April 12.
"While we believe the BMY/CELG merger is still likely to take place, we see increased risk to the transaction ahead of the special shareholder meeting on April 12," Huang said.
BofA said it has removed its investment opinion on Celgene, as it believes the shares of the company no longer trade on fundamentals.
Celgene shares were sliding 7.42 percent to $84.24 at the time of publication Thursday, while Bristol-Myers Squibb shares were up 1.95 percent at $51.96.
Related Links:
Novavax Re-Enters Penny Stock Territory After Respiratory Disease Vaccine Flunks Late-Stage Trial
Mylan's Disappointing Outlook Rattles Analysts, Investors
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.